DOCSLIB.ORG

Effects of Antialdosteronics on Plasmatic Hormonal Levels and on Hepatic Sexual Steroid Receptors in Rat

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Antialdosteronics on Plasmatic Hormonal Levels and on Hepatic Sexual Steroid Receptors in Rat Effects of Antialdosteronics on Plasmatic Hormonal Levels and on Hepatic Sexual Steroid Receptors in Rat A. Di Leo!, P.K. Eagon3, L. Polimeno!, F.W. Guglielmini!, I i' G. Fanizza2 , M. Barone!, G. Zizza!, A.M. Aquilino!, R. Ferrara!, A. Giangasperol, T.E. Starzl4 and A. Francavilla! 1 Dept. of Gastroenterology and 2 Dept. of Obstetrics and Gynecology, University of Bari, Bari, Italy 3 Dept. of Medicine and 4 Dept. of Surgery, Univesity of Pittsburgh, Pittsburgh, Pennsylvania Spironolactone and potassium canrenoate are diuretics widely used for management of cirrhotic ascites. The administration of spironolactone frequently leads to feminization, which has been noted less frequently with the use of potassium canrenoate, a salt of the active metabolite of spironolactone. The use of these two drugs has been associated with decreases in serum testos­ terone levels and in case of spironolactone with a reduction in androgen receptor (AR) activity (8,10,19,20,23,25-28). Considering the critical role of the liver in sex hormone me­ tabolism the study about the effects of these drugs on liver sex hormone receptor state, could add new informations for under­ standing the mechanism of feminization by these two drugs. We report here the effect of spironolactone and potassium canrenoate treatment on the sex hormone receptor and androgen responsive protein status of the liver and the effects of these treatments on serum estrogen and testosteron levels. MATERIALS AND METHODS Animals Three groups of adult male Sprague Dawley rats (240 gr b.w.) were studied. Animals in the control group (group 1) were 242 ANTIALDOSTERONIC DIURETICS AND RAT LIVER ANTIA. injected intraperitoneally with 0.5 ml of a solution of physiologic salin with TWEEN 80 (0.1% v/v). The rats in the other groups received 5 mg of spironolactone (group 2) or 5 mg of Protein conCt potassium canrenoate (group 3) dissolved in the same vehicle. All DNA concentr. animals were injected daily for 21 days and killed by decapita­ method of Burto tion after that time. Cytosolic r the basis of 3 Materials rected for yel receptor conten Estradiol (E2) and Dihydrotestosterone were purchased from bound/mg DNA re Steraloids, Wilton, NH. Spironolactone and Potassium Canrenoate rected for the were from SPA, Milan, Italy. Diethylstilbestrol (DEB), Leupeptin, animal, the tot Benzamidine, Bovine serum Albumin, Sodium Molybdate, Protamine the cytosolic a Sulfate and other buffer component were purchased from Sigma Cytosolic cont Chemical Co., St. Louis, MO. Norit A and Dextran C were obtained activity of ale from Fisher Scientific Co., Pittsburgh, PA. Radioactive and the washe (2,4,6,7,16,17)- 3H -E2 (131 Ci/rnrnol), 17 -methyl- 3H - 0.5% of that f methyltrienolone (3H -RI881) (79 Ci/rnrnol) and nonradioactive recovery of D R1881 were obtained from New England Nuclear, Boston, MA. In­ the homogenate. stagel scintillation fluid was purchased from Packard Instrument Serum testos Co., Downers Grove, IL. The radiolabeled steroids used in these mined by specif studies were assayed periodically for purity by thin layer Equilibrium chromatography on silica gel G in ethyl acetate/hexane/ethanol tions of bindin (85:10:5), and were used only if purity was> 95%. (35) . Statistical Assay of nuclear and cytosolic Sex-Steroid receptors program. Radioactivit Nuclear and cytosolic Sex-Steroid receptors were evaluated by ard TriCarb 543 the method previously described by us (11,14,16-18). Assay of androgen-responsive male estrogen binding protein In spironol Assay for the determination of cytosolic content of a male decrease in tes specific estrogen binding protein (MEB) has been described pre­ hormone levelt' viously (12,34). Briefly, cytosol is pre incubated for 1 h at 0 °c trol animals. with· 500 nM DES to block the estrogen receptor. The cytosol is observed in c· then incubated with 5 nM 3H-E2 in the absence and presence of significant red 5 M unlabeled E2 for 2 h a 0 °c. Bound and free steroids are Cytosolic At; separated by centrifuge-assisted BioGel P-6 chromatography (34). renoate treate This assay is quantitative for MEB and is linear over a broad control animal" range of protein concentration. variations in groups studied 0.25+0.08 nM tively (Tab I). ~"':~",_~~:t\!' ">- . - ~ .. Il'ER ANTIALDOSTEIWNIC D/URETICS AND l?/IT LIVER 2-13 solution of Other methods " in the other or 5 mg of Protein concentrations: method of Bradford (5). <2 vehicle. All DNA concentrations of homogenates and nuclear preparations: by decapita- method of Burton (6). Cytosolic receptor content for each animal was calculated on the basis of 3H -steroid bound/mg cytosol protein, and then cor- rected for yeld of cytosolic protein for gram of liver. Nuclear receptor content was calculated on the basis of 3H -steroid 'urchased from bound/mg DNA recovered in the nuclear preparation, and then cor­ Lum Canrenoate rected for the DNA content of the original homogenate. For each l), Leupeptin, animal, the total liver content of receptor represents the sum of ~e, Protamine the cytosolic and nuclear content based on 1 gram of liver. sed from Sigma Cytosolic contamination of nuclei was assayed by determining the were obtained activity of alcohol dehydrogenase (37) in the homogenate, cytosol Radioactive and the washed nuclei preparation and was found to be less than -methyl- 3H - 0.5% of that found in the nuclear preparation. The average :lonradioactive recovery of DNA in the nuclear preparation was 72.8% of that in :on, MA. In­ the homogenate. lrd Instrument Serum testosterone, estradiol and other hormones were deter­ used in these mined by specific radioimmunoassays as described previously (38). 1y thin layer Equilibrium dissociation constants (Kd's) and the concentra­ :exane/ethanol tions of binding sites were calculated by the method of Scatchard (35) • Statistical analyses were performed using the Student's t-test program. Radioactivity content of samples was determined using a Pack­ ; evaluated by ard TriCarb 5430 Liquid Scintillation System. RESULTS ~ng protein In spironolactone treated animals there is a significant of a male decrease in testosterone levels; all other gonadal and pituitary :escribed pre­ hormone levels in this group are comparable to those of the con­ r 1 h at 0 °c trol animals. In potassium canrenoate treated rats no change was he cytosol is observed in either testosterone or estradiol levels, although presence of significant reductions in progesterone and DHEAS was found. steroids are Cytosolic AR levels (cAR) are significantly higher in K can­ 19raphy (34). renoate treated rats as compared with those observed in either - over a broad control animals or spironolactone treated ones. There were no variations in the affinity of the cAR for its ligand in any groups studied. The Kd values for cAR were 0.26+0.06 nM, 0.25+0.08 nM and 0.31+0.04 nM for group I, II and III respec­ tively (Tab I). 244 ANTIALDOSTERONIC DIURETICS AND RAT LIVER ANTIA The activity of nuclear androgen receptor (nAR) , however, to sacrifice (1- presents a markedly different picture, and is significantly ra ts is ac tuall- decreased in the animals treated with either spironolactone or To determin· potassium canrenoate. competing for a­ As a result of these variations, the total AR content of the they were cap liver changed significantly only in those animals treated with an in vitro ass spironolactone (50% decrease from normal levels). Interestingly, Spironolac to' the activity of total androgen receptors in the spironolactone effective as treated animals shows a decrease proportional to that of plasma cytosol. Howeve­ testosterone. effective comp, canrenoate is i; Tab I: Variation in specific 3H -R1881 in rat liver any concentrati\ The activit: 3H -R1881 specific binding (fmol/g liver) were virtually of cER for E2 v, TOTAL NUCLEUS CYTOSOL PLASMA TESTOSTERONE were 0.26-+{).07 1 (NG/ML) and III respect: (nER) was decree CONTROL 364+62 202+46 162+9.9 1. 77+0.23 treated animal~ content does not SPIRO 170+38 26+7 144+24 0.78+0.20 latter finding (P<0.05) (P<0.05) (P<0.05) values in these K-CAN 347+61 21+8 326+42 1. 53+0. 32 Tab III: Variati (P<0.05) (P<0.05) liver 31- As total hepatic androgen receptor activity and plasma testosterone values were reduced in the spironolactone-treated TOTAl animals, the activity of a hepatic androgen responsive protein, a male specific estrogen binder (MEB), was also assessed (Tab II). CONTROL 623+11 Tab II: Activity of an androgen responsive protein in rat liver SPIRO 549+8' MEB (pmol/mg protein) CONTROL 2.41+1 K-CAN 650+2:': SPIRO o K-CANREO 6.3+1.5 (p<0.05) Sexual dimorp \ The activity of this protein is undetectable in the livers of animals and huma) the spironolactone treated animals; this loss of MEB activity is In male rat: comparable to that seen in rats castrated at least 15 days prior . LIVER ANTIALDOSTERONIC DIURETICS AND RAT LIVER 245 nAR) , however, to sacrifice (14,36). However MEB level in k-carenoate treated Ls significantly rats is actually higher than that observed in the control tats. Ii Lronolactone or To determine whether either of these drugs might interfer by \.' :j , I competing for androgen binding to its receptor, we tested whether ,;' ,i R content of the they were capable of competing for androgen receptor binding in ,; treat.ed with an in vitro assay. Interestingly, Spironolactone, at a 100 and 1000-fold excess, is partially spironolactone effective as a competitor for 3H - R188l binding in rat liver u that of plasma cytosol. However, the strong androgen R188l and DHT are much more effective competitors than is spironolactone. In contrast, k­ canrenoate is incapable of competing for 3H - R1881 binding at ver any concentration tested.
Load more

Recommended publications
  • Estradiol-17Β Pharmacokinetics and Histological Assessment Of
    animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season).
    [Show full text]
  • Exposure to Female Hormone Drugs During Pregnancy
    British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low.
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • Efficacy of Ethinylestradiol Re-Challenge for Metastatic Castration-Resistant Prostate Cancer
    ANTICANCER RESEARCH 36: 2999-3004 (2016) Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer TAKEHISA ONISHI1, TAKUJI SHIBAHARA1, SATORU MASUI1, YUSUKE SUGINO1, SHINICHIRO HIGASHI1 and TAKESHI SASAKI2 1Department of Urology, Ise Red Cross hospital, Ise, Japan; 2Department of Urology, Mie University Graduate School of Medicine, Tsu, Japan Abstract. Background: There has recently been renewed corticosteroids, estrogens, sipuleucel T and, more recently, interest in the use of estrogens as a treatment strategy for CYP17 inhibitor (abirateron acetate) and androgen castration-resistant prostate cancer (CRPC). The purpose of receptor antagonist (enzaltamide) (2-7). Treatment with this study was to evaluate the feasibility and efficacy of estrogens was used as a palliative therapy for advanced ethinylestradiol re-challenge (re-EE) in the management of prostate cancer, however, the discovery of luteinizing CRPC. Patients and Methods: Patients with metastatic CRPC hormone-releasing hormone (LH-RH) agonists led them to who received re-EE after disease progression on prior EE become less common and they stopped being used in most and other therapy were retrospectively reviewed for prostate- countries in the 1980s (8). One of the reasons for reduction specific antigen (PSA) response, PSA progression-free in their use is the risk of cardiovascular and survival (P-PFS) and adverse events. Results: Thirty-six re- thromboembolic events during therapy. However, several EE treatments were performed for 20 patients. PSA response reports demonstrated the positive oncological results of to the initial EE treatment was observed in 14 (70%) patients. therapy with estrogens, such as diethylstilbestrol (DES) PSA response to re-EE was 33.3% in 36 re-EE treatments.
    [Show full text]
  • A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
    Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies.
    [Show full text]
  • Diethylstilbestrol Lignant Cervical and Vaginal Tumors (Polyps, Squamous-Cell Papilloma, and Myosarcoma) in Female Hamsters, and Benign and Malignant Tes­ CAS No
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Diethylstilbestrol lignant cervical and vaginal tumors (polyps, squamous­cell papilloma, and myosarcoma) in female hamsters, and benign and malignant tes­ CAS No. 56-53-1 ticular tumors (granuloma, adenoma, and leiomyosarcoma) in male hamsters. Prenatal exposure also caused uterine cancer (adenocarci­ Known to be a human carcinogen noma) in female mice and hamsters, benign ovarian tumors (cystad­ First listed in the First Annual Report on Carcinogens (1980) enoma and granulosa­cell tumors) in female mice, and benign lung Also known as DES, diethylstilboestrol, or stilboestrol tumors (papillary adenoma) in mice of both sexes. Prenatal expo­ sure did not cause tumors in monkeys observed for up to six years CH 3 after birth. Mice developed cervical and vaginal tumors after receiv­ H2C ing a single subcutaneous injection of diethylstilbestrol on the first C OH day of life, and male rats developed cancer of the reproductive tract HO C (squamous­cell carcinoma) after receiving daily subcutaneous injec­ CH2 tions for the first month of life. Diethylstilbestrol also caused cancer in experimental animals ex­ H3C Carcinogenicity posed as adults. When administered orally, diethylstilbestrol caused cancer of the mammary gland (carcinoma and adenocarcinoma) in Diethylstilbestrol is known to be a human carcinogen based on suffi­ mice of both sexes and benign mammary­gland tumors (fibroade­ cient evidence of carcinogenicity from studies in humans. noma) in rats of both sexes. In addition, cancer of the cervix and uterus (adenocarcinoma), vagina (squamous­cell carcinoma), and Cancer Studies in Humans bone (osteosarcoma) occurred in mice, and benign and malignant The strongest evidence for carcinogenicity comes from epidemiolog­ pituitary­gland and liver tumors (hepatocellular tumors and heman­ ical studies of women exposed to diethylstilbestrol in utero (“diethyl­ gioendothelioma) occurred in rats.
    [Show full text]
  • Effect of Spironolactone and Potassium Canrenoate on Cytosolic and Nuclear Androgen and Estrogen Receptors of Rat Liver
    GASTROENTEROLOGY 1987;93:681-6 Effect of Spironolactone and Potassium Canrenoate on Cytosolic and Nuclear Androgen and Estrogen Receptors of Rat Liver ANTONIO FRANCAVILLA, ALFREDO DJ LEO, PATRICIA K. EAGON, LORENZO POLIMENO, FRANCESCO GUGLIELMI, GIUSEPPE F ANIZZA, MICHELE BARONE, and THOMAS E. STARZL Departments of Gastroenterology and Obstetrics and Gynecology, University of Bari, Bari, Italy; Departments of Medicine and Surgery, University of Pittsburgh, School of Medicine, and Veterans Administration Medical Center, Pittsburgh, Pennsylvania Spironolactone and potassium canrenoate are di­ spironolactone. This reduction in hepatic AR con­ uretics that are used widely for management of tent suggested loss of androgen responsiveness of cirrhotic ascites. The administration of spironolac­ liver. We confirmed this by assessing levels of MEB , tone frequently leads to feminization, which has and found that livers from group 2 animals had no been noted less frequently with the use of potassium detectable MEB activity, whereas livers from both canrenoate, a salt of the active metabolite of spi­ group 1 and 3 had normal MEB activity. No changes ronolactone. The use of these two drugs has been were observed in nuclear ER and cytosolic ER of associated with decreases in serum testosterone lev­ group 3 as compared with group 1. Nuclear estrogen els and spironolactone with a reduction in androgen receptor decreased and cytosolic ER increased in receptor (AR) activity. This decrease in AR has been group 2, but with no change in total ER content. cited as the cause of the anti androgen effect of these These results indicate that (a) only spironolactone drugs. We therefore assessed the effect of both drugs appears to act as an antiandrogen in liver, resulting on levels of androgen and estrogen receptors (ER) in in a decrease in both AR and male specific estrogen the liver, a tissue that is responsive to sex steroids.
    [Show full text]
  • Vivelle Estradiol Transdermal System Contains Estradiol in a Multipolymeric Adhesive
    T2000-08 89008101 Vivelle® estradiol transdermal system Continuous delivery for twice-weekly application Rx only Prescribing Information ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA IN POSTMENOPAUSAL WOMEN. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that "natural" estrogens are more or less hazardous than "synthetic" estrogens at equiestrogenic doses. DESCRIPTION The Vivelle estradiol transdermal system contains estradiol in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin. Five systems are available to provide nominal in vivo delivery of 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day via skin of average permeability. Each corresponding system having an active surface area of 7.25, 11.0, 14.5, 22.0 or 29.0 cm2 contains 2.17, 3.28, 4.33, 6.57, or 8.66 mg of estradiol USP, respectively. The composition of the systems per unit area is identical. Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5 (10)-triene-3,17ß-diol. The structural formula is OH CH3 H H H H HO The molecular formula of estradiol is C18H24O2. The molecular weight is 272.39. The Vivelle system comprises three layers. Proceeding from the visible surface toward the surface attached to the skin,
    [Show full text]
  • Estrogen As Therapy for Breast Cancer James N Ingle
    Available online http://breast-cancer-research.com/content/4/4/133 Commentary Estrogen as therapy for breast cancer James N Ingle Mayo Clinic, Rochester, Minnesota, USA Correspondence: James N Ingle, MD, Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel: +1 507 284 2511; fax: +1 507 284 1803; e-mail: [email protected] Received: 21 March 2002 Breast Cancer Res 2002, 4:133-136 Revisions requested: 26 April 2002 This article may contain supplementary data which can only be found Revisions received: 29 April 2002 online at http://breast-cancer-research.com/content/4/4/133 Accepted: 2 May 2002 © 2002 BioMed Central Ltd Published: 15 May 2002 (Print ISSN 1465-5411; Online ISSN 1465-542X) Abstract High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen. Subsequently, the use of estrogen was largely abandoned. Recent clinical trial data have shown clinically meaningful efficacy for high- dose estrogen even in patients with extensive prior endocrine therapy. Preclinical research has demonstrated that the estrogen dose–response curve for breast cancer cells can be shifted by modification of the estrogen environment. Clinical and laboratory data together provide the basis for developing testable hypotheses of management strategies, with the potential of increasing the value of endocrine therapy in women with breast cancer. Keywords: breast cancer, dose–response, endocrine therapy, estrogen Introduction following the establishment of tamoxifen as the standard, High-dose estrogen was the endocrine treatment of estrogens largely disappeared from the endocrine therapy choice in postmenopausal women with advanced breast mindset of practicing oncologists, being relegated to the cancer prior to the introduction of tamoxifen in the 1970s.
    [Show full text]
  • Hydroxysteroid Dehydrogenase
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 144, number 2 FEBS LETTERS August 1982 Norethisterone does not inhibit rat testis A5- 3/?-hydroxysteroid dehydrogenase J. Spona Endocrine Research Unit, First Department of Obstetrics and Gynecology, University of Vienna, A 1090 Vienna, Austria Received 10 June 1982 Norethisterone as-3P-hydroxysteroid dehydrogenase Rat testis 1. INTRODUCTION and stored at - 20” C. The cyanoketone used was 2~ cyano- 4,4,17cu~trimethylandrost-5-en-17fi-ol-3-one. A key step in the biosynthesis of progesterone /3-Nicotinamide adenine dinucleotide was pur- and of androgens is the production of A4-3-keto- chased from Sigma Chem. Co. (St Louis MO). All steroids from A5-3/I-hydroxysteroids [ 11. This enzy- other chemicals were of analytical grade and were matic conversion is a two step process in which obtained from Sigma, Boehringer or Merck AG dehydrogenation is followed by isomerization 121. (Darmstadt). The first step is rate limiting, and the enzyme which mediates the dehydrogenation is A5-3&hydroxy- 2.1. Enzyme extraction from rat testes steroid dehydrogenase (EC 1.1.1.145); it can be Testes of adult male rats of the Sprague-Dawley found in extracts of Pseudomonas testosteroni [3] strain (Himberg; Oncins, specific-pathogen free, and is localized in the microsomes and mitochon- 200-250 g body wt were obtained from For- dria of all steroid synthesizing organs such as schungsinstitut fur Versuchstierzucht, University of adrenal, ovary, placenta and testis [4]. Vienna. The animals were used 2 weeks after ship- The enzymes from mammalian and bacterial ment.
    [Show full text]
  • Independent Human Prostate Cancer Cell Lines
    [CANCER RESEARCH 62, 5365–5369, September 15, 2002] Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis in Androgen- independent Human Prostate Cancer Cell Lines Isaac Yi Kim, Byung-Chul Kim, Do Hwan Seong, Dug Keun Lee, Jeong-Meen Seo, Young Jin Hong, Heung-Tae Kim, Ronald A. Morton, and Seong-Jin Kim1 Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892 [I. Y. K., B. C. K., D. H. S., D. K. L., J-M. S., H-T. K., S-J. K.]; Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030 [I. Y. K., R. A. M.]; and Clinical Research Center, College of Medicine, Inha University, Inchon, South Korea 400-711 [Y. J. H.] ABSTRACT metastasis. After androgen withdrawal, there is a dramatic decrease in PSA with improvement in clinical parameters. However, prostate Raloxifene, a selective estrogen receptor (ER) modulator, is a mixed cancer cells inevitably become resistant to the androgen-withdrawal estrogen agonist/antagonist that has been shown to prevent osteoporosis therapy with a median time of 18–24 months (5). Once the hormone and breast cancer in women. Because the prostate contains high levels of ER-␤, the present study investigated the effect of raloxifene in three refractory prostate cancer emerges, treatment is largely limited to well-characterized, androgen-independent human prostate cancer cell palliative care. lines: (a) PC3; (b) PC3M; and (c) DU145. Reverse transcriptase-PCR and Raloxifene is the prototypical SERM that has been shown to Western blot analysis for ER-␣ and ER-␤ demonstrated that all three cell prevent osteoporosis and breast cancer (6, 7); other well-known mem- lines express ER-␤, whereas only PC3 and PC3M cells were positive for bers of SERMs include tamoxifene, droloxifene, and idoxifene.
    [Show full text]
  • History of Diethylstilbestrol Use in Cattle1
    History of diethylstilbestrol use in cattle1 A. P. Raun*2 and R. L. Preston3 *Eagles Nest Ranch, Elbert, CO 80106 ABSTRACT: The first demonstration of growth stim- ing cattle rations was rapidly adopted. Diethylstilbes- ulation in cattle with hormone supplementation took trol implants were cleared by the Food and Drug Admin- place in 1947 by investigators at Purdue University istration for use in cattle in 1957. Later developments using diethylstilbestrol (DES) in heifers. These studies defined the optimal dosage and form of orally adminis- on DES used a compressed tablet as a subcutaneous tered DES. A low incidence of DES residues in the livers implant. Side-effects, such as vulvar swelling, riding, of cattle were later found and were associated with and mammary development, were observed. Scientists misuse. These residues, along with the report of adeno- at Iowa State College later investigated the efficacy carcinoma in daughters of mothers treated with pre- of DES administered orally. Growth stimulation and improved feed utilization were observed in both sheep scription DES during pregnancy, led the Food and Drug and cattle, and fewer side-effects were reported with Administration to remove oral DES for cattle from the oral use. These studies also demonstrated reduced car- market in 1972 and implants the following year. The cass grade and increased leanness. Orally administered removal of DES from the market led to the development DES for cattle was approved by the U.S. Food and Drug of a number of other growth stimulation products for Administration in 1954, and its use in growing-finish- cattle. Key Words: Anabolic Steroids, Cattle, Diethylstilbestrol, Growth Promoters, History, Sheep 2002 American Society of Animal Science.
    [Show full text]